realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Inclusion criteria

• ✓. Age ≥18 years at the time of diagnosis of R/R DLBCL
• ✓. Initiated or initiating tafasitamab treatment
• ✓. R/R DLBCL patients who have received at least one (1) prior line of treatment for DLBCL
• ✓. Histologically confirmed DLBCL such as:
• ✓. Signed and dated ICF by the patient or the patient's Legally Acceptable Representative (LAR), for patients with prospective data collection, as applicable. For deceased or otherwise unreachable patients, no informed consent will be obtained for data collection in the study, provided that the competent Independent Ethics Committee (IEC)/Institutional Review Board (IRB) has provided favorable opinion and that any other local regulatory requirements on this matter are met